Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by johnny007on Jul 03, 2020 2:09pm
88 Views
Post# 31221547

More than 20% below offering now, MCAP < $50M

More than 20% below offering now, MCAP < $50MIt's been a long time.

Silently traded the stock - as we know, you shall always have some at these prices for the next run.

Now to the point, they are finally selling some tests havin EUA status (antibody) read?
Some indirect soft promotion via podcasts?
CEO mentions Aristotle again with a registered mark?

Offering was 7c with Warrants 9c. Not as supeb as the previous one,
still nice as it was not a VWAP offer.

Balance sheet looking better, not too bad.

What usually happens at this point now is the next run up, we all know it.
If they can show real revenues - maybe a real run up holding longer than just a week or two,
but such a sustainable run would really need support by hard numbers.

Anyways, guess it will hit at least $49M mcap in the next happening.
But I don't watch this board and stock only on price alarm and once in a while.
Good luck.

And greetings to Nailbiter as always.


Bullboard Posts